Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases

Molecular Neurodegeneration

Volumn 12, Issue 1, 2017, Pages

  Zhou, Zhi Dong ^a,c   Tan, Eng King ^a,b,c  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Amyloid precursor protein; Human neurodegenerative diseases; Iron; Iron binding proteins; Iron responsive element; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; IRON REGULATORY FACTOR; APP PROTEIN, HUMAN; IRON;

5' UNTRANSLATED REGION; DEGENERATIVE DISEASE; DOWN REGULATION; HUMAN; IRON CHELATION; IRON HOMEOSTASIS; IRON METABOLISM; IRON RESPONSIVE ELEMENT; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; HOMEOSTASIS; METABOLISM; PHYSIOLOGY;

ALPHA-SYNUCLEIN; AMYLOID BETA-PROTEIN PRECURSOR; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; IRON; IRON-REGULATORY PROTEINS; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

EID: 85032223131     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/s13024-017-0218-4     Document Type: Review

References (136)

1. The mineral nutrition of livestock, 3rd ed. Br J Nutr. 2000; 84: 393.
2. Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 2001;33:940-59.
3. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol. 2005;202:199-211.
4. Fontecave M, Pierre JL. Iron: metabolism, toxicity and therapy. Biochimie. 1993;75:767-73.
5. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J. 2011;434:365-81.
6. Fleming MD. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program. 2008;1:151-8.
7. Anderson GJ, Frazer DM, McKie AT, Vulpe CD. The ceruloplasmin homolog hephaestin and the control of intestinal iron absorption. Blood Cells Mol Dis. 2002;29:367-75.
8. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142:24-38.
9. Horowitz MP, Greenamyre JT. Mitochondrial iron metabolism and its role in neurodegeneration. J Alzheimers Dis. 2010;20(Suppl 2):S551-68.
10. Philpott CC, Ryu MS. Special delivery: distributing iron in the cytosol of mammalian cells. Front Pharmacol. 2014;5:173.
11. Ganz T. Cellular iron: ferroportin is the only way out. Cell Metab. 2005;1:155-7.
12. Koeppen AH. The history of iron in the brain. J Neurol Sci. 1995;134(Suppl):1-9.
13. Koeppen AHA. Brief history of brain iron research. J Neurol Sci. 2003;207:95-7.
14. Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci. 2004;1012:193-208.
15. Hare D, Ayton S, Bush A, Lei PA. Delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci. 2013;5:34.
16. Hurtado EK, Claussen AH, Scott KG. Early childhood anemia and mild or moderate mental retardation. Am J Clin Nutr. 1999;69:115-9.
17. Cortese S, Azoulay R, Castellanos FX, Chalard F, Lecendreux M, Chechin D, Delorme R, Sebag G, Sbarbati A, Mouren MC, et al. Brain iron levels in attention-deficit/hyperactivity disorder: a pilot MRI study. World J Biol Psychiatry. 2012;13:223-31.
18. Konofal E, Cortese S, Lecendreux M, Arnulf I, Mouren MC. Effectiveness of iron supplementation in a young child with attention-deficit/hyperactivity disorder. Pediatrics. 2005;116:e732-4.
19. Ghanizad A. Regarding the effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol. 2008;39:73. author reply 73-4
20. Youdim MB, Ben-Shachar D, Yehuda S. Putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior. Am J Clin Nutr. 1989;50:607-15. discussion 615-7
21. Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG, Earley CJ. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61:304-9.
22. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5:863-73.
23. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13:1045-60.
24. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, Elstner M, Morris CM. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology. 2007;68:1820-5.
25. Li K, Besse EK, Ha D, Kovtunovych G, Rouault TA. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum Mol Genet. 2008;17:2265-73.
26. Wilson RB. Iron dysregulation in Friedreich ataxia. Semin Pediatr Neurol. 2006;13:166-75.
27. Kurian MA, McNeill A, Lin JP, Maher ER. Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). Dev Med Child Neurol. 2011;53:394-404.
28. Mehnaaz L. Neurodegeneration with brain iron accumulation (NBIA) formerly Hallervorden- Spatz disease. J Assoc Physicians India. 2016;64:132.
29. Fernaeus S, Reis K, Bedecs K, Land T. Increased susceptibility to oxidative stress in scrapie-infected neuroblastoma cells is associated with intracellular iron status. Neurosci Lett. 2005;389:133-6.
30. Olsen MK, Roberds SL, Ellerbrock BR, Fleck TJ, McKinley DK, Gurney ME. Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol. 2001;50:730-40.
31. Gray NK, Hentze MW. Iron regulatory protein prevents binding of the 43S translation pre-initiation complex to ferritin and eALAS mRNAs. EMBO J. 1994;13:3882-91.
32. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci. 2004;1012:1-13.
33. Zhang DL, Ghosh MC, Rouault TA. The physiological functions of iron regulatory proteins in iron homeostasis - an update. Front Pharmacol. 2014;5:124.
34. Piccinelli P, Samuelsson T. Evolution of the iron-responsive element. RNA. 2007;13:952-66.
35. Kato J, Kobune M, Ohkubo S, Fujikawa K, Tanaka M, Takimoto R, Takada K, Takahari D, Kawano Y, Kohgo Y, et al. Iron/IRP-1-dependent regulation of mRNA expression for transferrin receptor, DMT1 and ferritin during human erythroid differentiation. Exp Hematol. 2007;35:879-87.
36. Ma J, Haldar S, Khan MA, Sharma SD, Merrick WC, Theil EC, Goss DJ. Fe2+ binds iron responsive element-RNA, selectively changing protein-binding affinities and regulating mRNA repression and activation. Proc Natl Acad Sci U S A. 2011;109:8417-22.
37. Fu D, Richardson DR. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood. 2007;110:752-61.
38. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle. 2007;6:1982-94.
39. Sanchez M, Galy B, Muckenthaler MU, Hentze MW. Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol. 2007;14:420-6.
40. Nurtjahja-Tjendraputra E, Fu D, Phang JM, Richardson DR. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood. 2007;109:4045-54.
41. Kayed R, Jackson GR, Estes DM, Barrett AD. Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins. J Cent Nerv Syst Dis. 2011;3:67-73.
42. Abbasowa L, Heegaard NHA. Systematic review of amyloid-beta peptides as putative mediators of the association between affective disorders and Alzheimers disease. J Affect Disord. 2014;168:167-83.
43. Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J. Amyloid-beta: a crucial factor in Alzheimer's disease. Med Princ Pract. 2014;24:1-10.
44. Rovelet-Lecrux A, Frebourg T, Tuominen H, Majamaa K, Campion D, Remes AMAPP. Locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 2007;78:1158-9.
45. Guyant-Marechal L, Rovelet-Lecrux A, Goumidi L, Cousin E, Hannequin D, Raux G, Penet C, Ricard S, Mace S, Amouyel P, et al. Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology. 2007;68:684-7.
46. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis. 2009;16:879-95.
47. Rogers JT, Bush AI, Cho HH, Smith DH, Thomson AM, Friedlich AL, Lahiri DK, Leedman PJ, Huang X, Cahill CM. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans. 2008;36:1282-7.
48. Bandyopadhyay S, Huang X, Cho H, Greig NH, Youdim MB, Rogers JT. Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator. J Neural Transm Suppl. 2006;71:237-47.
49. Cahill CM, Lahiri DK, Huang X, Rogers JT. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta. 2009;1790:615-28.
50. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem. 2002;277:45518-28.
51. Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, Rogers JT. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem. 2010;285:31217-32.
52. Tucker S, Ahl M, Cho HH, Bandyopadhyay S, Cuny GD, Bush AI, Goldstein LE, Westaway D, Huang X, Rogers JTRNA. Therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Curr Alzheimer Res. 2006;3:221-7.
53. Maccecchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig NH. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry. 2013;83:894-902.
54. Tahmasebinia F, Emadi S. Effect of metal chelators on the aggregation of beta-amyloid peptides in the presence of copper and iron. Biometals. 2017;30:285-93.
55. Khan MA, Quadri SA, Tohid HA. Comprehensive overview of the neuropsychiatry of Parkinson's disease: a review. Bull Menn Clin. 2017;81:53-105.
56. Venuto CS, Potter NB, Ray Dorsey E, Kieburtz KA. Review of disease progression models of Parkinson's disease and applications in clinical trials. Mov Disord. 2016;31:947-56.
57. Salvatore MF, Fisher B, Surgener SP, Gerhardt GA, Rouault T. Neurochemical investigations of dopamine neuronal systems in iron-regulatory protein 2 (IRP-2) knockout mice. Brain Res Mol Brain Res. 2005;139:341-7.
58. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E, Drake SK, Miller G, Abu-Asab M, Tsokos M, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet. 2001;27:209-14.
59. Weiss G, Goossen B, Doppler W, Fuchs D, Pantopoulos K, Werner-Felmayer G, Wachter H, Hentze MW. Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway. EMBO J. 1993;12:3651-7.
60. Jaffrey SR, Cohen NA, Rouault TA, Klausner RD, Snyder SH. The iron-responsive element binding protein: a target for synaptic actions of nitric oxide. Proc Natl Acad Sci U S A. 1994;91:12994-8.
61. Ayton S, Lei P, Hare DJ, Duce JA, George JL, Adlard PA, McLean C, Rogers JT, Cherny RA, Finkelstein DI, et al. Parkinson's disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. J Neurosci. 2015;35:3591-7.
62. Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M. Alpha-Synuclein expression is modulated at the translational level by iron. Neuroreport. 2012;23:576-80.
63. Li WJ, Jiang H, Song N, Xie JX. Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells. Neurosci Bull. 2010;26:205-10.
64. Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. Neurobiol Dis. 2017;17:30080-3.
65. Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein E, Schwarz TC, Ledolter K, Bonhaus D, Paulino A, Eleuteri S, et al. A de novo compound targeting alpha-synuclein improves deficits in models of Parkinson's disease. Brain. 2016;139:3217-36.
66. Lindstrom V, Ihse E, Fagerqvist T, Bergstrom J, Nordstrom E, Moller C, Lannfelt L, Ingelsson M. Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. Immunotherapy. 2014;6:141-53.
67. Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology. 2007;27:494-506.
68. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106-8.
69. Vaughan J, Durr A, Tassin J, Bereznai B, Gasser T, Bonifati V, De Michele G, Fabrizio E, Volpe G, Bandmann O, et al. The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European consortium on genetic susceptibility in Parkinson's disease. Ann Neurol. 1998;44:270-3.
70. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord. 2013;28:811-3.
71. Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, Kitami T, Sato K, Kuroda R, Tomiyama H, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol. 2006;59:298-309.
72. Bradbury J. Alpha-synuclein gene triplication discovered in Parkinson's disease. Lancet Neurol. 2003;2:715.
73. Rogers JT, Mikkilineni S, Cantuti-Castelvetri I, Smith DH, Huang X, Bandyopadhyay S, Cahill CM, Maccecchini ML, Lahiri DK, Greig NH. The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transm (Vienna). 2011;118:493-507.
74. QS Y, Reale M, Kamal MA, Holloway HW, Luo W, Sambamurti K, Ray B, Lahiri DK, Rogers JT, Greig NH. Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, alpha-Synuclein synthesis, interleukin-1beta release, and cholinergic action. Antiinflamm Antiallergy Agents Med Chem. 2013;12:117-28.
75. Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the alpha-synuclein rAAV Parkinson's model. Exp Neurol. 2013;247:45-58.
76. Finkelstein DI, Hare DJ, Billings JL, Sedjahtera A, Nurjono M, Arthofer E, George S, Culvenor JG, Bush AI, Adlard PA. Clioquinol improves cognitive, motor function, and microanatomy of the alpha-Synuclein hA53T transgenic mice. ACS Chem Neurosci. 2016;7:119-29.
77. Gajowiak A, Stys A, Starzynski RR, Staron R, Lipinski P. Misregulation of iron homeostasis in amyotrophic lateral sclerosis. Postepy Hig Med Dosw (Online). 2016;70:709-21.
78. Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P, David S. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci. 2009;29:610-9.
79. Takei Y, Oguchi K, Koshihara H, Hineno A, Nakamura A, Ohara S. Alpha-Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 gene mutation. Hum Pathol. 2013;44:1171-6.
80. Koch Y, Helferich AM, Steinacker P, Oeckl P, Walther P, Weishaupt JH, Danzer KM, Otto M. Aggregated alpha-Synuclein increases SOD1 oligomerization in a mouse model of amyotrophic lateral sclerosis. Am J Pathol. 2016;186:2152-61.
81. Yu J, Qi F, Wang N, Gao P, Dai S, Lu Y, Su Q, Du Y, Che F. Increased iron level in motor cortex of amyotrophic lateral sclerosis patients: an in vivo MR study. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:357-61.
82. Ignjatovic A, Stevic Z, Lavrnic S, Dakovic M, Bacic G. Brain iron MRI: a biomarker for amyotrophic lateral sclerosis. J Magn Reson Imaging. 2013;38:1472-9.
83. Deschauer M, Gaul C, Behrmann C, Prokisch H, Zierz S, Haack TB. C19orf12 mutations in neurodegeneration with brain iron accumulation mimicking juvenile amyotrophic lateral sclerosis. J Neurol. 2012;259:2434-9.
84. Golko-Perez S, Mandel S, Amit T, Kupershmidt L, Youdim MB, Weinreb O. Additive neuroprotective effects of the multifunctional iron chelator M30 with enriched diet in a mouse model of amyotrophic lateral sclerosis. Neurotox Res. 2016;29:208-17.
85. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2009;23:3766-79.
86. Wang Q, Zhang X, Chen S, Zhang X, Zhang S, Youdium M, Le W. Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis. 2011;8:310-21.
87. Qureshi M, Brown RH Jr, Rogers JT, Cudkowicz ME. Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol J. 2008;2:51-4.
88. DeMeo DL, Mariani T, Bhattacharya S, Srisuma S, Lange C, Litonjua A, Bueno R, Pillai SG, Lomas DA, Sparrow D, et al. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet. 2009;85:493-502.
89. Miyajima H. Genetic disorders affecting proteins of iron and copper metabolism: clinical implications. Intern Med. 2002;41:762-9.
90. Aguilar-Martinez P, Schved JF, Brissot P. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am J Gastroenterol. 2005;100:1185-94.
91. Cao W, McMahon M, Wang B, O'Connor R, Clarkson MA. Ccase report of spontaneous mutation (C33>U) in the iron-responsive element of L-ferritin causing hyperferritinemia-cataract syndrome. Blood Cells Mol Dis. 2010;44:22-7.
92. Kato J, Fujikawa K, Kanda M, Fukuda N, Sasaki K, Takayama T, Kobune M, Takada K, Takimoto R, Hamada H, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet. 2001;69:191-7.
93. Cazzola M, Bergamaschi G, Tonon L, Arbustini E, Grasso M, Vercesi E, Barosi G, Bianchi PE, Cairo G, Arosio P. Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. Blood. 1997;90:814-21.
94. Liu W, Shimomura S, Imanishi H, Iwamoto Y, Ikeda N, Saito M, Ohno M, Hara N, Yamamoto T, Nakamura H, et al. Hemochromatosis with mutation of the ferroportin 1 (IREG1) gene. Intern Med. 2005;44:285-9.
95. Mok H, Jelinek J, Pai S, Cattanach BM, Prchal JT, Youssoufian H, Schumacher A. Disruption of ferroportin 1 regulation causes dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice. Development. 2004;131:1859-68.
96. Levi S, Cozzi A, Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract Res Clin Haematol. 2005;18:265-76.
97. Garringer HJ, Irimia JM, Li W, Goodwin CB, Richine B, Acton A, Chan RJ, Peacock M, Muhoberac BB, Ghetti B, et al. Effect of systemic iron overload and a chelation therapy in a mouse model of the neurodegenerative disease hereditary Ferritinopathy. PLoS One. 2016;11:e0161341.
98. Friedman A, Arosio P, Finazzi D, Koziorowski D, Galazka-Friedman J. Ferritin as an important player in neurodegeneration. Parkinsonism Relat Disord. 2011;17:423-30.
99. Luscieti S, Santambrogio P, Langlois d'Estaintot B, Granier T, Cozzi A, Poli M, Gallois B, Finazzi D, Cattaneo A, Levi S, et al. mutant ferritin L-chains that cause neurodegeneration act in a dominant-negative manner to reduce ferritin iron incorporation. J Biol Chem. 2010;285:11948-57.
100. Muhoberac BB, Baraibar MA, Vidal R. Iron loading-induced aggregation and reduction of iron incorporation in heteropolymeric ferritin containing a mutant light chain that causes neurodegeneration. Biochim Biophys Acta. 1812;2011:544-8.
101. Vidal R, Miravalle L, Gao X, Barbeito AG, Baraibar MA, Hekmatyar SK, Widel M, Bansal N, Delisle MB, Ghetti B. Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. J Neurosci. 2008;28:60-7.
102. Cotter PD, May A, Fitzsimons EJ, Houston T, Woodcock BE, Al-Sabah AI, Wong L, Bishop DF. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest. 1995;96:2090-6.
103. Cox TC, Bottomley SS, Wiley JS, Bawden MJ, Matthews CS, May BKX. Linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med. 1994;330:675-9.
104. Whatley SD, Ducamp S, Gouya L, Grandchamp B, Beaumont C, Badminton MN, Elder GH, Holme SA, Anstey AV, Parker M, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet. 2008;83:408-14.
105. Mayr R, Griffiths WJ, Hermann M, McFarlane I, Halsall DJ, Finkenstedt A, Douds A, Davies SE, Janecke AR, Vogel W, et al. Identification of mutations in SLC40A1 that affect ferroportin function and phenotype of human ferroportin iron overload. Gastroenterology 2011; 140: 2056-2063, 2063 e1.
106. De Domenico I, Ward DM, Musci G, Kaplan J. Iron overload due to mutations in ferroportin. Haematologica. 2006;91:92-5.
107. Mims MP, Guan Y, Pospisilova D, Priwitzerova M, Indrak K, Ponka P, Divoky V, Prchal JT. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood. 2005;105:1337-42.
108. Lam-Yuk-Tseung S, Camaschella C, Iolascon A, Gros P. A novel R416C mutation in human DMT1 (SLC11A2) displays pleiotropic effects on function and causes microcytic anemia and hepatic iron overload. Blood Cells Mol Dis. 2006;36:347-54.
109. Iolascon A, d'Apolito M, Servedio V, Cimmino F, Piga A, Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood. 2006;107:349-54.
110. Bandyopadhyay S, Cahill C, Balleidier A, Huang C, Lahiri DK, Huang X, Rogers JT. Novel 5′ untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease. PLoS One. 2013;8:e65978.
111. Lilja AM, Luo Y, QS Y, Rojdner J, Li Y, Marini AM, Marutle A, Nordberg A, Greig NH. Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease. PLoS One. 2013;8:e54887.
112. Lahiri DK, Chen D, Maloney B, Holloway HW, QS Y, Utsuki T, Giordano T, Sambamurti K, Greig NH. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther. 2007;320:386-96.
113. Shaw KT, Utsuki T, Rogers J, QS Y, Sambamurti K, Brossi A, Ge YW, Lahiri DK, Greig NH. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A. 2001;98:7605-10.
114. Morse LJ, Payton SM, Cuny GD, Rogers JT. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J Mol Neurosci. 2004;24:129-36.
115. Maccecchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig NH. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry. 2012;83:894-902.
116. Bandyopadhyay S, Rogers JT. Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis. Biochem Pharmacol. 2014;88:486-94.
117. Payton S, Cahill CM, Randall JD, Gullans SR, Rogers JT. Drug discovery targeted to the Alzheimer's APP mRNA 5′-untranslated region: the action of paroxetine and dimercaptopropanol. J Mol Neurosci. 2003;20:267-75.
118. Ross NT, Metkar SR, Le H, Burbank J, Cahill C, Germain A, MacPherson L, Bittker J, Palmer M, Rogers J, et al. Identification of a small molecule that selectively inhibits alpha-synuclein translational expression. Probe reports from the NIH molecular libraries. Program. 2011
119. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A. 1991;88:10540-3.
120. Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets. 2004;5:535-51.
121. Jiang H, Luan Z, Wang J, Xie J. Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem Int. 2006;49:605-9.
122. Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT. Novel drug targets based on metallobiology of Alzheimer's disease. Expert Opin Ther Targets. 2010;14:1177-97.
123. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 2003;60:1685-91.
124. Zhang YH, Raymick J, Sarkar S, Lahiri DK, Ray B, Holtzman D, Dumas M, Schmued LC. Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease. Curr Alzheimer Res. 2013;10:494-506.
125. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, et al. PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J Alzheimers Dis. 2010;20:509-16.
126. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008;7:779-86.
127. Adlard PA, Sedjahtera A, Gunawan L, Bray L, Hare D, Lear J, Doble P, Bush AI, Finkelstein DI, Cherny RA. A novel approach to rapidly prevent age-related cognitive decline. Aging Cell. 2013;13:351-9.
128. Adlard PA, Bica L, White AR, Nurjono M, Filiz G, Crouch PJ, Donnelly PS, Cappai R, Finkelstein DI, Bush AI. Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS One. 2011;6:e17669.
129. Xu Q, Kanthasamy AG, Reddy MB. Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease. Toxicology. 2008;245:101-8.
130. Ghosh B, Antonio T, Reith ME, Dutta AK. Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperaz in-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease. J Med Chem. 2010;53:2114-25.
131. Dexter DT, Statton SA, Whitmore C, Freinbichler W, Weinberger P, Tipton KF, Della Corte L, Ward RJ, Crichton RR. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm (Vienna). 2011;118:223-31.
132. Bar-Am O, Amit T, Kupershmidt L, Aluf Y, Mechlovich D, Kabha H, Danovitch L, Zurawski VR, Youdim MB, Weinreb O. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-a/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging. Neurobiol Aging. 2015;36:1529-42.
133. Das B, Kandegedara A, Xu L, Antonio T, Stemmler T, Reith MEA, Dutta AKA. Novel iron(II) preferring dopamine agonist chelator as potential symptomatic and neuroprotective therapeutic agent for Parkinson's disease. ACS Chem Neurosci. 2017;8:723-30.
134. Beaumont C, Leneuve P, Devaux I, Scoazec JY, Berthier M, Loiseau MN, Grandchamp B, Bonneau D. Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nat Genet. 1995;11:444-6.
135. Athan ES, Lee JH, Arriaga A, Mayeux RP, Tycko B. Polymorphisms in the promoter of the human APP gene: functional evaluation and allele frequencies in Alzheimer disease. Arch Neurol. 2002;59:1793-9.
136. Coon KD, Siegel AM, Yee SJ, Dunckley TL, Mueller C, Nagra RM, Tourtellotte WW, Reiman EM, Papassotiropoulos A, Petersen FF, et al. Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer's disease. J Alzheimers Dis. 2006;9:225-33.